Tissue Responsiveness Is Not Uniform
The same patient, with the same systemic treatment, will often observe that different affected areas of their body respond quite differently to treatment. An axillary region that has been involved for two years may show meaningful improvement — reduced nodule frequency, softening of previously firm areas, partial healing of early sinus formation — while a groin region that has been affected for eight years shows stabilisation of active inflammation but minimal change in the established structural features that accumulated during those years of disease.
This is not a failure of treatment to work in certain areas. It is a reflection of a real biological difference: the tissue in the long-affected region is structurally different from the tissue in the shorter-affected region. It has undergone more fibrotic remodelling, more vascular change, more loss of normal follicular architecture. Its capacity to respond to the change in internal environment that treatment produces is lower — not because the internal environment has not changed, but because the tissue that is supposed to benefit from that change has been altered structurally in ways that limit how much recovery is possible.
Understanding why this happens requires looking at what inflammation actually does to tissue over time — and why some of those changes are reversible while others are not.
"To understand why this condition keeps recurring, it's important to look beyond the surface and examine the internal processes involved."
What Inflammation Does to Tissue Over Time
Acute inflammation in HS produces tissue changes that are, in principle, reversible: swelling from fluid accumulation, increased vascular permeability, recruitment of immune cells that can be resolved once the inflammatory episode resolves. This is the tissue state of an early or acute HS lesion — painful, active, but operating within a tissue environment that has not yet been permanently altered.
Repeated acute inflammation, sustained over months and years, progressively shifts the tissue from this reversible acute state to a state characterised by permanent structural change. The mechanisms of this shift operate at several levels simultaneously.
Fibrotic Remodelling
Repeated inflammatory episodes activate fibroblasts — the cells responsible for producing collagen in connective tissue. In a normally resolving inflammatory episode, fibroblast activity contributes to controlled healing. In chronic, recurring inflammation, fibroblast activation becomes persistent, producing excess collagen deposition that gradually replaces the normal tissue architecture with dense fibrous tissue.
The resulting fibrosis is mechanically and biologically distinct from normal tissue. It is stiffer, less vascular, and less capable of supporting the normal cellular processes of immune surveillance, tissue repair, and follicular function. Fibrotic tissue does not regenerate to its pre-fibrotic state when inflammation reduces — the collagen that has been deposited remains, and the normal structures that the collagen replaced are not restored. This is the primary reason why areas with advanced fibrosis show limited structural improvement even when systemic treatment is effective at reducing inflammatory activity.
Follicular Architecture Loss
HS originates in the hair follicle — follicular occlusion is the initiating event in lesion formation. In early disease, the follicular structures in affected areas are anatomically present, even if functionally impaired. In areas of long-standing repeated disease, repeated follicular rupture, abscess formation, and the subsequent inflammatory response progressively destroy follicular architecture. The follicular units that were the site of original disease activity are replaced by scar tissue and fibrous tracts.
This follicular loss has two implications for tissue responsiveness. First, the areas of destroyed follicular architecture cannot produce new HS lesions — a form of partial self-limitation that explains why the most chronically affected areas sometimes become less acutely active over time. Second, the normal tissue functions supported by follicular structures — including aspects of local immune surveillance and skin barrier integrity — are reduced in areas where follicular architecture has been lost, leaving the tissue less capable of normal repair responses even when systemic inflammation is reduced.
Microvascular Alteration
Chronic inflammation in HS produces progressive changes in the microvasculature of affected areas — the small blood vessels that supply oxygen and nutrients to the tissue and support the cellular processes of healing and repair. As described in the context of microvascular damage in HS, repeated inflammatory episodes alter vessel architecture, reduce functional vessel density, and impair the delivery of healing mediators to inflamed tissue.
Tissue with significantly compromised microvasculature has reduced capacity for healing responses even when the systemic inflammatory environment improves, because the local delivery of the cellular components of repair — immune regulatory cells, healing growth factors, the metabolic substrates of tissue rebuilding — depends on functional microvasculature that has been damaged by years of inflammatory activity. This is a local factor in tissue responsiveness that operates independently of systemic treatment effectiveness.
In Ayurvedic understanding, tissue healing depends on the quality and accessibility of Ojas — the refined product of healthy tissue metabolism — and on the integrity of the Srotas (channels) through which nourishment and healing reach the tissues. In HS-affected areas with advanced structural change, the local Srotas are obstructed and the tissue quality is diminished by accumulated Ama and Dhatu degradation. Systemic Shodhana and Rasayana treatment improves the overall quality of tissue nourishment, but the degree to which this improvement can express locally depends on the integrity of local channels and tissues. Severely obstructed local Srotas may require external therapeutic support — specialised topical applications and local procedures — alongside systemic correction, to achieve meaningful local tissue response.
The Spectrum of Tissue Responsiveness
Tissue responsiveness in HS exists on a spectrum from full reversibility to structural permanence, with most affected areas falling somewhere between these extremes depending on disease duration and severity in that specific location.
High responsiveness — early and moderate change. Areas affected for shorter periods, with primarily inflammatory rather than fibrotic change, retain substantial capacity for improvement when the internal environment changes. Active nodules and abscesses in relatively unaltered tissue can resolve more completely. Early sinus formation, before epithelialisation is established, can partially regress when inflammation reduces. Tissue in this category shows the most visible treatment response and the most encouraging early improvement.
Moderate responsiveness — established but not complete fibrosis. Areas with moderate fibrotic change — firmness, mild sinus formation, early scarring — show partial improvement. Active inflammatory components resolve more fully; established structural features improve less. These areas typically show reduced tenderness, reduced active lesion formation, and some softening of fibrotic tissue over time, but do not return fully to pre-disease tissue character.
Low responsiveness — advanced structural change. Areas with dense fibrosis, established sinus networks, and significant follicular architecture loss show the least structural response to internal treatment. Active inflammation within and adjacent to these areas can be reduced, preventing further damage. But the established structural features — the dense fibrous tissue, the epithelialised tracts, the areas of follicular loss — are not reversed by internal correction alone. Stabilisation rather than reversal is the realistic local treatment goal in these areas.
"HS is not a skin problem. It is a systemic inflammatory condition expressing through the skin."
What Tissue Responsiveness Means for Treatment Expectations
Understanding the spectrum of tissue responsiveness allows for more accurate local treatment expectation-setting — which is particularly important for patients who have areas of long-standing disease alongside areas of more recent involvement.
In the same patient, different affected areas may be at different points on the responsiveness spectrum. A realistic treatment outcome for that patient includes more substantial improvement in areas of higher responsiveness and stabilisation with partial improvement in areas of lower responsiveness. Expecting uniform improvement across all affected areas — as a benchmark for whether treatment is working — will produce a misleading assessment, because the areas with advanced structural change are not expected to respond as fully as areas with less established disease.
The clinically important objectives in low-responsiveness areas are: preventing further structural damage (stopping the progression that has produced the current state), reducing active inflammation that is uncomfortable and producing ongoing damage in adjacent tissue, and creating the most supportive possible local environment for whatever degree of healing the tissue retains capacity for. These are meaningful objectives even when full reversal is not achievable, and achieving them constitutes genuine treatment success in those areas.
Local Support as a Complement to Systemic Correction
In areas of reduced tissue responsiveness, systemic correction alone may produce less local improvement than the overall treatment response would suggest. In these cases, local therapeutic support — carefully selected external applications that support tissue healing, reduce local inflammatory activity, and improve microcirculation in affected areas — can complement systemic treatment by addressing the local tissue environment directly, rather than relying entirely on systemic changes to translate into local improvement through compromised tissue channels.
This is not a substitution for systemic correction — it is a complement to it. Local applications without systemic correction address the tissue environment without changing the internal drivers that generated the damage. Systemic correction without local support in severely damaged areas may achieve the best possible systemic outcome while still leaving local tissue with limited capacity to express that improvement. The combination produces the most complete response available in low-responsiveness areas.
Identifying which areas require this combined approach — and tailoring the local supportive element to the specific tissue state and disease character of each area — is part of the personalised assessment that distinguishes serious clinical management of HS from standardised treatment protocols applied uniformly.